https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accounts-receivable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-bonuses-current-and-noncurrent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-income-taxes https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-insurance-current-and-noncurrent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-liabilities-and-other-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-liabilities-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-payroll-taxes-current-and-noncurrent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-royalties-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accrued-salaries-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/acquisition-consideration-transferred-liabilities-incurred https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/acquisition-contingent-consideration-liability-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/acquisition-contingent-consideration-liability-noncurrent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/acquisitions https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/activist-13d-13g-form-schedule-13g https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/additional-paid-in-capital https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/adjustments-related-to-tax-withholding-for-share-based-compensation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/amended-reports-10-k https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/amended-reports-10-q https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/amortization https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/amortization-of-financing-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/aoci https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/asset-impairment-charges https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/available-for-sale-debt-change-in-present-value-expense-reversal https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/available-for-sale-debt-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/buyback-authorization https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/buybacks-treasury-shares-acquired https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/buybacks-treasury-stock-cost https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cash-and-cash-equivalents-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/clinical-trials https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/concept-patents-allegedly-infringed-number-tag-2 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contract-liability https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-after-fifth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-in-fifth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-in-fourth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-in-second-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-due-in-third-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/contractual-obligation-future-minimum-payments-due-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cost-of-goods-sold https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cost-of-revenue https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cost-of-revenue-2 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/costs-and-expenses https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-issued https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-after-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-in-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-periodic-payment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-repaid https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/debt-securities-held-to-maturity-credit-loss-expense-reversal https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-finance-costs-noncurrent-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-finance-costs-noncurrent-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-income-tax-assets-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-income-tax-liabilities-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-income-taxes-and-tax-credits https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-rent-credit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-charitable-contribution-carryforwards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-inventory https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-foreign https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-bonuses https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-compensation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-reserves https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-returns-and-allowances https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-deferred-expense-capitalized-inventory-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-deferred-expense-capitalized-patent-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-leasing-arrangements https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/deferred-tax-liabilities-prepaid-expenses https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/depreciation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/depreciation-and-amortization https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/derivative-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/derivative-gain-loss-on-derivative-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/derivative-liabilities-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/dilutive-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/dividends-preferred-stock https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/due-from-related-parties https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/effective-tax-rate https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/embedded-derivative-fair-value-of-embedded-derivative-asset https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/eps https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/eps-basic https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/fair-value-liabilities-obligations https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/foreign-currency-contract-asset-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/foreign-currency-contracts-liability-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/form-d-stocks https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/gain-loss-related-to-litigation-settlement https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/goodwill https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/goodwill-change https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/goodwill-impairment-loss https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/goodwill-purchase-accounting-adjustments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/gross-profit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/income-taxes-paid-2 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-contract-with-customer-liability https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-decrease-in-other-noncurrent-assets-and-liabilities-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/increase-in-utb-is-reasonably-possible https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/incremental-common-shares-attributable-to-call-options-and-warrants https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/insider-transactions-other https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/insider-transactions-preferred https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/insider-transactions-warrants https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/interest-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/interest-expense-on-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/interest-expense-other https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/interest-paid-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory-finished-goods https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory-raw-materials https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory-work-in-process https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory-work-in-process-and-raw-materials-net-of-reserves https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/inventory-write-down https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/investment-income-interest https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/investments-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/lease-and-rental-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/lease-cost https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/lease-incentive-receivable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/liabilities-fair-value-adjustment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/liabilities-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/litigation-settlement-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/long-term-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/marketing-and-advertising-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/maturities-of-shortterm-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/net-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/noncash-or-part-noncash-acquisition-value-of-liabilities-assumed https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/nonfinancial-liabilities-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/number-of-reportable-segments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-gain-loss-arising-net-of-tax https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/oci-net-of-tax https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-expenses https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-cost https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-liability https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-liability-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-right-of-use-asset-amortization-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-assets-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-current-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-nonoperating-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/other-sales-revenue-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/paid-in-capital-convertible-debt-with-conversion-feature https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/paid-in-capital-other https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/paid-in-capital-share-based-compensation-and-exercise-of-stock-options https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/patents-active https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/patents-pending https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/patents-rejected https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-of-financing-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-businesses-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-equity-securities-fv-ni https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-notes-receivable https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/payments-to-acquire-short-term-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-stock-dividend-rate-percentage https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/preferred-stock-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/prepaid-insurance https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/prepaid-taxes https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/pretax-income https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-issuance-of-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-issuance-of-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-license-fees-received https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-lines-of-credit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-sale-maturity-and-collection-of-shortterm-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/professional-fees https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/public-float https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-after-fifth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-in-fifth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-in-fourth-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-in-second-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-due-in-third-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/purchase-obligation-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/receivables-fair-value-disclosure https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/receivables-long-term-contracts-or-programs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/repayments-of-lines-of-credit https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/restructuring-costs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/restructuring-reserve-current https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/revenue https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/royalty-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/royalty-revenue https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sales-revenue-net https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-comment-letters-drsltr https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-comment-letters-sec-staff-letter https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-10-k https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-10-q https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-10-qt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-15-12g https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-25 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-8-a12b https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-8-k https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-ars https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-ct-order https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-def-14a https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-defa14a https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sec-filings-regdex https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-drs https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-fwp https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-rw https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-s-1mef https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/sga-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/short-term-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-shares-issued-for-stock-awards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-shares-issued-shares-new-issues https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-nonvested-options-forfeited-number-of-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-exercisable-number https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/stock-repurchase-program-remaining-number-of-shares-authorized-to-be-repurchased https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-cuts-and-jobs-act-incomplete-accounting-change-in-tax-rate-deferred-tax-asset-provisional-income-tax-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense-meals-and-entertainment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-other-reconciling-items-percent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-rate-reconciliation-tax-cuts-and-jobs-act-percent https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/temporary-equity-dividends-adjustment https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/total-liabilities https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/total-long-term-debt https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/treasury-stock-common-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/treasury-stock-common-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/treasury-stock-shares https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/treasury-stock-value https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/unamortized-debt-issuance-expense https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/unrealized-gain-loss-on-investments https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/warrants-and-rights-outstanding https://stock.noler.com/us/stock/eagle-pharmaceuticals-inc/weighted-average-number-of-share-outstanding-basic-and-diluted